Imaging agent for PD-L1 on solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial uses a special injectable imaging agent (a 'probe') that lights up a protein called PD-L1 on your tumor cells. It helps doctors see your tumors more clearly on a PET scan, which may guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have a solid tumor (not a blood cancer)
- Your tumors can be seen on a CT or MRI scan
- You are expected to live at least 3 more months
- You do not have severe liver or kidney problems
- You are not pregnant, breastfeeding, or planning to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
This trial studies whether a special PET scan probe that targets CLDN18.2 can help show solid tumors in the body. If you have a solid tumor that can be measured on scan, you may be invited to have imaging with the probe.
This trial tests a new imaging agent that targets a protein called CD147, which is found on many solid tumors. The goal is to see if this agent can help doctors better stage your cancer using a PET/CT scan.
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
This study tests an imaging method that looks for PD-L1 (a protein linked to some cancers) in solid tumors, including gastrointestinal cancers. It may help doctors better see where PD-L1 is in the body using a scan.
This trial tests a new imaging agent that targets TF-antigen, a molecule found on many solid tumors. The goal is to see if a PET scan can better detect and monitor cancers like lung, breast, or colon cancer.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.